✦ LIBER ✦

Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

✍ Scribed by Schreiber, Stefan; Feagan, Brian; D’Haens, Geert; Colombel, Jean–Frederic; Geboes, Karel; Yurcov, Mikhail; Isakov, Vasily; Golovenko, Oleg; Bernstein, Charles N.; Ludwig, Diether; Winter, Trevor; Meier, Ulrich; Yong, Chan; Steffgen, Jürgen

Book ID: 121774970
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 218 KB
Volume: 4
Category: Article
ISSN: 1542-3565
DOI: 10.1016/j.cgh.2005.11.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Etanercept for Active Crohn's Disease: A

Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

✍ William J. Sandborn; Stephen B. Hanauer; Seymour Katz; Michael Safdi; Douglas G. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 181 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease

✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des

S1066 Oral Alpha-4 Integrin Inhibitor (A

S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial

✍ Masakazu Takazoe; Mamoru Watanabe; Takaaki Kawaguchi; Takayuki Matsumoto; Nobuhi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 100 KB

A 24-Week, Randomized, Double-Blind, Pla

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis

✍ Genovese, Mark C. (author);Cohen, Stanley B. (author);Wofsy, David (author);Wein 📂 Article 📅 2011 🏛 Journal of Rheumatology Publishing Company 🌐 English ⚖ 320 KB

A 24-Week, Randomized, Double-Blind, Pla

✍ Genovese, Mark C. (author);Cohen, Stanley B. (author);Wofsy, David (author);Wein 📂 Article 📅 2011 🏛 Journal of Rheumatology Publishing Company 🌐 English ⚖ 320 KB

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

✍ Bruce E. Sands; Eric W. Jacobson; Thomas Sylwestrowicz; Ziad Younes; Gerald Dryd 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB 👁 1 views

## Background: Interleukin-12 (il-12) and interleukin-23 (il-23) are inflammatory cytokines linked to the th-1 and th-17 phenotypes associated with crohn's disease (cd). we investigated the activity and safety of apilimod mesylate (formerly sta-5326), an oral il-12 and il-23 inhibitor, in patients